Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

Michael Millward(The University of Western Australia), Matthew A. Spear(Poseida Therapeutics (United States)), Kristine C. Federico(Supernus Pharmaceuticals (United States)), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Steffan T. Nawrocki(University of Arizona), Natasha Reddinger(Supernus Pharmaceuticals (United States)), Monica Mita(Novartis (Switzerland)), G. Kenneth Lloyd(Culham Centre for Fusion Energy), Alain C. Mita(Cedars-Sinai Medical Center)
Investigational New Drugs
February 15, 2011
10.1007/s10637-011-9642-4
Cited by 74

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530